Innovation in pharma
Disparities remain on how to tackle lung cancer in Europe, report says
Enhanced prevention measures, especially against tobacco and electronic cigarettes, combined with access to innovative treatments can help tackle rising lung cancer cases in Europe, a new study funded by the industry has found.
Romanian health minister: Prevention and innovative drugs to kill cancer
In order to face the rising cancer incidence across Europe, governments should prioritise prevention policies, as well as access to innovative medicines under an EU-wide plan, Romanian Health Minister Sorina Pintea told EURACTIV.com in an interview.
Greek pharma boss: ‘We reached our limits, our sustainability is at stake’
The Greek pharmaceutical industry has reached its limits due to a number of “unreasonable” burdens imposed by the government during the crisis, Greek pharma chief Olympios Papadimitriou told EURACTIV.com in an interview. The sustainability of pharma companies is at stake, threatening 86,000 jobs, he said.
Does fast-track drugs approval in EU run too fast?
More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foster innovation and remaining abuse-proof.
EU generics industry slams US ‘intervention’ in SPC manufacturing waiver talks
The EU generics industry has accused the US government of intervening in the ongoing discussion in the EU on the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.
MEP: Need for an EU-wide cancer plan to ensure long-term pharma innovation
The creation of an EU cancer plan will improve EU citizens’ medical needs and access but will also simultaneously help bring innovations to the market, through enhanced collaboration among stakeholders, according to Belgian MEP Lieve Wierinck.
Innovation in oncology – Can science make cancer a manageable disease?
In Europe, more than 3 million people are diagnosed with cancer each year. But recent advances in cancer treatment have offered new hope to those battling the disease.
New drugs: how much are governments paying for innovation?
The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
Estonia and Finland first to start exchanging healthcare data by end of year
Estonia and Finland will start exchanging digital prescriptions at the end of the year, in a groundbreaking move that Estonian Health Minister Riina Sikkut said she hoped other EU countries will follow.
Europe’s health sector worried about post-Brexit investment dearth
Fragmented, multilingual and over-regulated: Europe is currently not an attractive place for investors and things could get worse after Brexit, experts from the life sciences industry have warned.
Investment in digital health and access to drugs at the core of Austrian Presidency
Austria’s EU Presidency will focus on “strong” investment in digital health as well as on regulatory issues when it comes to access to medicines, Dr Clemens Martin Auer told EURACTIV.com in an interview. Dr Clemens Martin Auer is the president of the...
EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
‘Vital’ UK remains part of EU clinical trials, say MPs
Continued participation in EU-wide clinical trials and the Horizon 2020 research programme is ‘vital’ to the UK’s life sciences sector, according to a new cross-party report by UK MPs.
EU and UK patients with rare diseases in Brexit limbo
It is still unclear whether the UK will participate after Brexit in the European Reference Networks, which aim to help patients with rare diseases, potentially putting at risk millions of patients.
Health care risks being forgotten in Brexit talks, industry warns
Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.
EU unveils health technology bill
The European Commission unveiled plans for a pan-EU Health Technology Assessment (HTA) law on Wednesday (31 January), with EU health chief Vytenis Andriukaitis promising that they would help patients take advantage of “an exciting era for innovation in health".
Fake medicines? Face 15 year jail term
Twenty-one EU countries have made falsifying medicines a criminal offence, carrying a potential jail sentence of 15 years, according to a new report published on Friday (26 January) by the European Commission.
Health expert: Europe should not put its dominant pharma innovation at risk
The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.
Commission reforms meet with national ‘silence’, says frustrated EU health chief
EU governments are meeting the Commission's proposals to reform health systems with "silence", an exasperated Health Commissioner Vytenis Andriukaitis said on Thursday (25 January), pleading for more investment in prevention across the bloc.
Health tech bill to kick off busy policy agenda in 2018
The European Commission will propose a new law on Health Technology Assessments to kick off a busy EU health agenda in 2018.
Stakeholders call for more transparent meetings between pharma and EMA
Public health organisations and EU lawmakers say the closed-door meetings before the submission of a new drug between the pharma industry and the European Medicines Agency (EMA), a key player in the continent’s healthcare industry, should be more transparent.
Commission reassures ‘worried’ member states on Health Technology Assessment
The Commission’s upcoming proposal on Health Technology Assessment (HTA) will focus on clinical aspects and leave member states to decide on economic or ethical parts, a European Commission spokesperson told EURACTIV.com.OpinionPromoted content
Drugs incentives have saved lives in Europe
Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.